Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma

Dale Han, Jonathan S. Zager, Yu Shyr, Heidi Chen, Lynne D. Berry, Sanjana Iyengar, Mia Djulbegovic, Jaimie L. Weber, Suroosh S. Marzban, Vernon K. Sondak, Jane L. Messina, John Vetto, Richard L. White, Barbara Pockaj, Nicola Mozzillo, Kim James Charney, Eli Avisar, Robert Krouse, Mohammed Kashani-Sabet, Stanley P. Leong

    Research output: Contribution to journalArticle

    123 Citations (Scopus)

    Abstract

    Purpose Indications for sentinel lymph node biopsy (SLNB) for thin melanoma are continually evolving. We present a large multi-institutional study to determine factors predictive of sentinel lymph node (SLN) metastasis in thin melanoma. Patients and Methods Retrospective review of the Sentinel Lymph Node Working Group database from 1994 to 2012 identified 1,250 patients who had an SLNB and thin melanomas (<1 mm). Clinicopathologic characteristics were correlated with SLN status and outcome. Results SLN metastases were detected in 65 (5.2%) of 1,250 patients. On univariable analysis, rates of Breslow thickness ≥ 0.75 mm, Clark level ≥ IV, ulceration, and absence of regression differed significantly between positive and negative SLN groups (all P <.05). These four variables and mitotic rate were used in multivariable analysis, which demonstrated that Breslow thickness ≥ 0.75 mm (P ≥ .03), Clark level ≥ IV (P ≥ .05), and ulceration (P ≥ .01) significantly predicted SLN metastasis with 6.3%, 7.0%, and 11.6% of the patients with these respective characteristics having SLN disease. Melanomas ≥ 0.75 mm had positive SLN rates of ≥ 5% regardless of Clark level and ulceration status. Median follow-up was 2.6 years. Melanoma-specific survival was significantly worse for patients with positive versus negative SLNs (P ≥ .001). Conclusion Breslow thickness ≥ 0.75 mm, Clark level ≥ IV, and ulceration significantly predict SLN disease in thin melanoma. Most SLN metastases (86.2%) occur in melanomas ≥ 0.75 mm, with 6.3% of these patients having SLN disease, whereas in melanomas ≥ 0.75 mm, SLN metastasis rates are ≥ 5%. By using a 5% metastasis risk threshold, SLNB is indicated for melanomas ≥ 0.75 mm, but further study is needed to define indications for SLNB in melanomas ≥ 0.75 mm.

    Original languageEnglish (US)
    Pages (from-to)4387-4393
    Number of pages7
    JournalJournal of Clinical Oncology
    Volume31
    Issue number35
    DOIs
    StatePublished - Dec 10 2013

    Fingerprint

    Melanoma
    Neoplasm Metastasis
    Sentinel Lymph Node Biopsy
    Sentinel Lymph Node
    Databases
    Survival

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology
    • Medicine(all)

    Cite this

    Han, D., Zager, J. S., Shyr, Y., Chen, H., Berry, L. D., Iyengar, S., ... Leong, S. P. (2013). Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. Journal of Clinical Oncology, 31(35), 4387-4393. https://doi.org/10.1200/JCO.2013.50.1114

    Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. / Han, Dale; Zager, Jonathan S.; Shyr, Yu; Chen, Heidi; Berry, Lynne D.; Iyengar, Sanjana; Djulbegovic, Mia; Weber, Jaimie L.; Marzban, Suroosh S.; Sondak, Vernon K.; Messina, Jane L.; Vetto, John; White, Richard L.; Pockaj, Barbara; Mozzillo, Nicola; James Charney, Kim; Avisar, Eli; Krouse, Robert; Kashani-Sabet, Mohammed; Leong, Stanley P.

    In: Journal of Clinical Oncology, Vol. 31, No. 35, 10.12.2013, p. 4387-4393.

    Research output: Contribution to journalArticle

    Han, D, Zager, JS, Shyr, Y, Chen, H, Berry, LD, Iyengar, S, Djulbegovic, M, Weber, JL, Marzban, SS, Sondak, VK, Messina, JL, Vetto, J, White, RL, Pockaj, B, Mozzillo, N, James Charney, K, Avisar, E, Krouse, R, Kashani-Sabet, M & Leong, SP 2013, 'Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma', Journal of Clinical Oncology, vol. 31, no. 35, pp. 4387-4393. https://doi.org/10.1200/JCO.2013.50.1114
    Han, Dale ; Zager, Jonathan S. ; Shyr, Yu ; Chen, Heidi ; Berry, Lynne D. ; Iyengar, Sanjana ; Djulbegovic, Mia ; Weber, Jaimie L. ; Marzban, Suroosh S. ; Sondak, Vernon K. ; Messina, Jane L. ; Vetto, John ; White, Richard L. ; Pockaj, Barbara ; Mozzillo, Nicola ; James Charney, Kim ; Avisar, Eli ; Krouse, Robert ; Kashani-Sabet, Mohammed ; Leong, Stanley P. / Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 35. pp. 4387-4393.
    @article{3c7d80abf70b413397197523d4affa03,
    title = "Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma",
    abstract = "Purpose Indications for sentinel lymph node biopsy (SLNB) for thin melanoma are continually evolving. We present a large multi-institutional study to determine factors predictive of sentinel lymph node (SLN) metastasis in thin melanoma. Patients and Methods Retrospective review of the Sentinel Lymph Node Working Group database from 1994 to 2012 identified 1,250 patients who had an SLNB and thin melanomas (<1 mm). Clinicopathologic characteristics were correlated with SLN status and outcome. Results SLN metastases were detected in 65 (5.2{\%}) of 1,250 patients. On univariable analysis, rates of Breslow thickness ≥ 0.75 mm, Clark level ≥ IV, ulceration, and absence of regression differed significantly between positive and negative SLN groups (all P <.05). These four variables and mitotic rate were used in multivariable analysis, which demonstrated that Breslow thickness ≥ 0.75 mm (P ≥ .03), Clark level ≥ IV (P ≥ .05), and ulceration (P ≥ .01) significantly predicted SLN metastasis with 6.3{\%}, 7.0{\%}, and 11.6{\%} of the patients with these respective characteristics having SLN disease. Melanomas ≥ 0.75 mm had positive SLN rates of ≥ 5{\%} regardless of Clark level and ulceration status. Median follow-up was 2.6 years. Melanoma-specific survival was significantly worse for patients with positive versus negative SLNs (P ≥ .001). Conclusion Breslow thickness ≥ 0.75 mm, Clark level ≥ IV, and ulceration significantly predict SLN disease in thin melanoma. Most SLN metastases (86.2{\%}) occur in melanomas ≥ 0.75 mm, with 6.3{\%} of these patients having SLN disease, whereas in melanomas ≥ 0.75 mm, SLN metastasis rates are ≥ 5{\%}. By using a 5{\%} metastasis risk threshold, SLNB is indicated for melanomas ≥ 0.75 mm, but further study is needed to define indications for SLNB in melanomas ≥ 0.75 mm.",
    author = "Dale Han and Zager, {Jonathan S.} and Yu Shyr and Heidi Chen and Berry, {Lynne D.} and Sanjana Iyengar and Mia Djulbegovic and Weber, {Jaimie L.} and Marzban, {Suroosh S.} and Sondak, {Vernon K.} and Messina, {Jane L.} and John Vetto and White, {Richard L.} and Barbara Pockaj and Nicola Mozzillo and {James Charney}, Kim and Eli Avisar and Robert Krouse and Mohammed Kashani-Sabet and Leong, {Stanley P.}",
    year = "2013",
    month = "12",
    day = "10",
    doi = "10.1200/JCO.2013.50.1114",
    language = "English (US)",
    volume = "31",
    pages = "4387--4393",
    journal = "Journal of Clinical Oncology",
    issn = "0732-183X",
    publisher = "American Society of Clinical Oncology",
    number = "35",

    }

    TY - JOUR

    T1 - Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma

    AU - Han, Dale

    AU - Zager, Jonathan S.

    AU - Shyr, Yu

    AU - Chen, Heidi

    AU - Berry, Lynne D.

    AU - Iyengar, Sanjana

    AU - Djulbegovic, Mia

    AU - Weber, Jaimie L.

    AU - Marzban, Suroosh S.

    AU - Sondak, Vernon K.

    AU - Messina, Jane L.

    AU - Vetto, John

    AU - White, Richard L.

    AU - Pockaj, Barbara

    AU - Mozzillo, Nicola

    AU - James Charney, Kim

    AU - Avisar, Eli

    AU - Krouse, Robert

    AU - Kashani-Sabet, Mohammed

    AU - Leong, Stanley P.

    PY - 2013/12/10

    Y1 - 2013/12/10

    N2 - Purpose Indications for sentinel lymph node biopsy (SLNB) for thin melanoma are continually evolving. We present a large multi-institutional study to determine factors predictive of sentinel lymph node (SLN) metastasis in thin melanoma. Patients and Methods Retrospective review of the Sentinel Lymph Node Working Group database from 1994 to 2012 identified 1,250 patients who had an SLNB and thin melanomas (<1 mm). Clinicopathologic characteristics were correlated with SLN status and outcome. Results SLN metastases were detected in 65 (5.2%) of 1,250 patients. On univariable analysis, rates of Breslow thickness ≥ 0.75 mm, Clark level ≥ IV, ulceration, and absence of regression differed significantly between positive and negative SLN groups (all P <.05). These four variables and mitotic rate were used in multivariable analysis, which demonstrated that Breslow thickness ≥ 0.75 mm (P ≥ .03), Clark level ≥ IV (P ≥ .05), and ulceration (P ≥ .01) significantly predicted SLN metastasis with 6.3%, 7.0%, and 11.6% of the patients with these respective characteristics having SLN disease. Melanomas ≥ 0.75 mm had positive SLN rates of ≥ 5% regardless of Clark level and ulceration status. Median follow-up was 2.6 years. Melanoma-specific survival was significantly worse for patients with positive versus negative SLNs (P ≥ .001). Conclusion Breslow thickness ≥ 0.75 mm, Clark level ≥ IV, and ulceration significantly predict SLN disease in thin melanoma. Most SLN metastases (86.2%) occur in melanomas ≥ 0.75 mm, with 6.3% of these patients having SLN disease, whereas in melanomas ≥ 0.75 mm, SLN metastasis rates are ≥ 5%. By using a 5% metastasis risk threshold, SLNB is indicated for melanomas ≥ 0.75 mm, but further study is needed to define indications for SLNB in melanomas ≥ 0.75 mm.

    AB - Purpose Indications for sentinel lymph node biopsy (SLNB) for thin melanoma are continually evolving. We present a large multi-institutional study to determine factors predictive of sentinel lymph node (SLN) metastasis in thin melanoma. Patients and Methods Retrospective review of the Sentinel Lymph Node Working Group database from 1994 to 2012 identified 1,250 patients who had an SLNB and thin melanomas (<1 mm). Clinicopathologic characteristics were correlated with SLN status and outcome. Results SLN metastases were detected in 65 (5.2%) of 1,250 patients. On univariable analysis, rates of Breslow thickness ≥ 0.75 mm, Clark level ≥ IV, ulceration, and absence of regression differed significantly between positive and negative SLN groups (all P <.05). These four variables and mitotic rate were used in multivariable analysis, which demonstrated that Breslow thickness ≥ 0.75 mm (P ≥ .03), Clark level ≥ IV (P ≥ .05), and ulceration (P ≥ .01) significantly predicted SLN metastasis with 6.3%, 7.0%, and 11.6% of the patients with these respective characteristics having SLN disease. Melanomas ≥ 0.75 mm had positive SLN rates of ≥ 5% regardless of Clark level and ulceration status. Median follow-up was 2.6 years. Melanoma-specific survival was significantly worse for patients with positive versus negative SLNs (P ≥ .001). Conclusion Breslow thickness ≥ 0.75 mm, Clark level ≥ IV, and ulceration significantly predict SLN disease in thin melanoma. Most SLN metastases (86.2%) occur in melanomas ≥ 0.75 mm, with 6.3% of these patients having SLN disease, whereas in melanomas ≥ 0.75 mm, SLN metastasis rates are ≥ 5%. By using a 5% metastasis risk threshold, SLNB is indicated for melanomas ≥ 0.75 mm, but further study is needed to define indications for SLNB in melanomas ≥ 0.75 mm.

    UR - http://www.scopus.com/inward/record.url?scp=84894363785&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84894363785&partnerID=8YFLogxK

    U2 - 10.1200/JCO.2013.50.1114

    DO - 10.1200/JCO.2013.50.1114

    M3 - Article

    C2 - 24190111

    AN - SCOPUS:84894363785

    VL - 31

    SP - 4387

    EP - 4393

    JO - Journal of Clinical Oncology

    JF - Journal of Clinical Oncology

    SN - 0732-183X

    IS - 35

    ER -